133626-83-2 Usage
Chemical class
Benzodiazepines
Psychoactive properties
Modulates the neurotransmitter gamma-aminobutyric acid (GABA) in the brain
Structural features
Contains an ethyl group, multiple methyl groups, and a pyrido-benzodiazepinone core structure
Known effects
Sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant properties
Common uses
Treating anxiety, insomnia, seizures, and muscle spasms
Pharmacological profile
Depends on specific interactions with GABA receptors and other molecular targets in the central nervous system
Molecular weight
Approximately 318.42 g/mol
Appearance
Likely a solid, possibly crystalline or amorphous
Solubility
Soluble in organic solvents such as methanol, ethanol, and dichloromethane; may have limited solubility in water
Stability
Stable under normal conditions, but sensitive to light, heat, and moisture
Metabolism
Likely metabolized in the liver by the cytochrome P450 system
Excretion
Primarily eliminated through the kidneys, with some metabolites potentially excreted in the feces
Side effects
Potential side effects may include drowsiness, dizziness, and dependence with long-term use
Drug interactions
May interact with other central nervous system depressants, as well as drugs that affect GABAergic transmission or liver metabolism
Check Digit Verification of cas no
The CAS Registry Mumber 133626-83-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,6,2 and 6 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 133626-83:
(8*1)+(7*3)+(6*3)+(5*6)+(4*2)+(3*6)+(2*8)+(1*3)=122
122 % 10 = 2
So 133626-83-2 is a valid CAS Registry Number.
133626-83-2Relevant articles and documents
Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones
Hargrave, Karl D.,Proudfoot, John R.,Grozinger, Karl G.,Cullen, Ernest,Kapadia, Suresh R.,et al.
, p. 2231 - 2241 (2007/10/02)
Novel pyridobenzodiazepinones (I), pyridobenzodiazepinones (II), and dipyridodiazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM.In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.In general, lipophilic substituents are preferred on the A ring, whereassubstitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings.Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.Additional substituents on the A ring can be readily tolerated.The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridodiazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.
